$LYEL News

B. Riley Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44

Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Citizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price Target

Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

Lyell Immunopharma Announces Data From Its Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-cell Lymphoma Shows Manufacturing Success Rate Of 97%

Lyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Is Lyell Immunopharma (NASDAQ:LYEL) In A Good Position To Deliver On Growth Plans?

HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $45 Price Target

Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

Lyell Immunopharma's Cancer Therapy Shows Improved Safety in Phase 1 Study

Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

Lyell Immunopharma Issues LYL273 Safety Profile Update In Its Ongoing U.S. Phase 1 Clinical Trial In Patients With Relapsed Or Refractory Metastatic Colorectal Cancer

Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

Lyell Immunopharma To Present Data From Its Current Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-Cell Lymphoma At European Hematology Association 2026 Congress

Lyell Immunopharma (LYEL) Loses 39.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $45 Price Target